{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT07183189","nct_id":"NCT07183189","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07183189. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"investigational treatment group：SHR-A2009 combined with Aumolertinib","type":"EXPERIMENTAL"},{"description":null,"label":"control group ：Aumolertinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-12","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":582,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"SHR-A2009 ; Aumolertinib","otherNames":[],"type":"DRUG"},{"name":"Aumolertinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","official_title":"A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) assessed by BICR according to RECIST v1.1","timeFrame":"Up to approximately 38 months"}],"references":[],"start_date":{"date":"2025-10-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","url":"https://clinicaltrials.gov/study/NCT07183189"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07183189"}